Spots Global Cancer Trial Database for chronic lymphocytic leukemia
Every month we try and update this database with for chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | NCT03513562 | Chronic Lymphoc... Ibrutinib Resis... | Ibrutinib Laboratory Biom... Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| ALICIA (Acalabrutinib in CLL Therapy) | NCT04746950 | Chronic Lymphoc... | - | AstraZeneca | ||
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | NCT02315768 | Chronic Lymphoc... | GA101 ibrutinib | 65 Years - | University of California, San Diego | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| Oral Valganciclovir Versus Valacyclovir | NCT00562770 | Chronic Lymphoc... Leukemia | Valganciclovir Valacyclovir | 16 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | NCT01021358 | Lymphoma Chronic Lymphoc... Solid Tumors | ABT-263 Ketoconazole | 18 Years - | Abbott | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia | NCT04964908 | Chronic Lymphoc... | 18 Years - | AstraZeneca | ||
| Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation | NCT01455051 | Chronic Lymphoc... | Ofatumumab | 18 Years - 70 Years | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| Gazyva Infusion Reaction Investigation | NCT03529227 | Chronic Lymphoc... | 18 Years - | Healthy Future | ||
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | NCT01392079 | Chronic Lymphoc... | Alemtuzumab | 18 Years - | University of Ulm | |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy | NCT00108108 | Chronic Lymphoc... | HCD122 | 18 Years - | Novartis | |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | NCT05959694 | Chronic Lymphoc... Small Lymphocyt... | TQB3909 tablet | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01539512 | Chronic Lymphoc... | Idelalisib Rituximab Placebo to matc... | 18 Years - | Gilead Sciences | |
| A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | NCT02717611 | Chronic Lymphoc... | ACP-196 (acalab... | 18 Years - | Acerta Pharma BV | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | NCT01403246 | Chronic Lymphoc... | Lenalidomide; C... | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00275054 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Rituximab | 18 Years - | German CLL Study Group | |
| Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia | NCT01849939 | Chronic Lymphoc... Lymphocytic Lym... | Fludarabin (pos... | 18 Years - 70 Years | University Hospital, Clermont-Ferrand | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | NCT04504708 | Non-hodgkin Lym... Chronic Lymphoc... Small Lymphocyt... | ZX-101A | 18 Years - | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | NCT03609593 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - 99 Years | Columbia University | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL | NCT02371590 | Chronic Lymphoc... | Lenalidomide Obinutuzumab | 18 Years - | University of California, San Diego | |
| Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | NCT00428233 | Chronic Lymphoc... | Leukemia cell h... | 18 Years - | Dana-Farber Cancer Institute | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT01767766 | Non-Hodgkin's L... Chronic Lymphoc... Peripheral T-Ce... Hodgkin's Lymph... | TGR-1202 | 18 Years - | TG Therapeutics, Inc. | |
| B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression | NCT01030913 | Chronic Lymphoc... | 18 Years - | Northwell Health | ||
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin's L... | Fludarabine + C... | 18 Years - | Wuhan Union Hospital, China | |
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | NCT01271283 | Chronic Lymphoc... Stage III Chron... Stage IV Chroni... | Diagnostic Labo... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | NCT01474681 | Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt... | HSC835 | 10 Years - 55 Years | Novartis | |
| Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia | NCT00274989 | Chronic Lymphoc... | Bendamustine Rituximab | 18 Years - | German CLL Study Group | |
| Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination | NCT00442130 | Chronic Lymphoc... | GM-K562 vaccine stem cell trans... | 18 Years - | Dana-Farber Cancer Institute | |
| Selenious Yeast in CLL Patients w/o Indication of Chemotherapy | NCT05136378 | Chronic Lymphoc... Chronic Lymphoc... Chronic Lymphoc... Chronic Lymphoc... | Low Dose Seleni... High Dose Selen... | 17 Years - 99 Years | Shanghai Zhongshan Hospital | |
| Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | NCT03447808 | Chronic Lymphoc... | Daratumumab Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Pneumococcal Vaccine in Untreated CLL Patients | NCT01892618 | Chronic Lymphoc... | Prevenar 13 Pneumovax | 18 Years - 90 Years | Karolinska University Hospital | |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | NCT04505254 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | NCT01346020 | Chronic Lymphoc... | - | Universitaire Ziekenhuizen KU Leuven | ||
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | NCT00758693 | Chronic Lymphoc... | Bendamustine Rituximab | 65 Years - | University of Kentucky | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | NCT00571662 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplastic... Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... Peripheral T-ce... | Pentostatin Total-body irra... Cyclosporine A ... Mycophenolate M... G-CSF | 19 Years - 75 Years | University of Nebraska | |
| Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | NCT05417165 | Chronic Lymphoc... Small Lymphocyt... | Pneumococcal 20... Pneumococcal Po... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | NCT01585688 | Non-Hodgkin's L... Chronic Lymphoc... | hLL1-DOX (IMMU-... | 18 Years - | Gilead Sciences | |
| Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) | NCT01144260 | B-Cell Chronic ... | bafetinib | 18 Years - | CytRx | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice | NCT03310190 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04852822 | Chronic Lymphoc... Small Lymphocyt... | Biospecimen Col... Electronic Heal... | 18 Years - | University of Washington | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | NCT02717611 | Chronic Lymphoc... | ACP-196 (acalab... | 18 Years - | Acerta Pharma BV | |
| Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT03986034 | Chronic Lymphoc... | During Venetocl... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan | NCT06362044 | Chronic Lymphoc... | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
